Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia
The purpose of this study is to find the maximum safe dose of nivolumab alone, and of nivolumab combined with azacitidine after reduced-intensity allogeneic peripheral blood stem cell (PBSC) transplantation. Another purpose is to see how the study drugs affect different aspects of transplant such as infection and disease response.
- IRB Number: 1905948967 (BTCRC-AML18-342)
- Research Study Identifier: TX10509
- Principal Investigator: Sherif Farag, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required